FDA Grants Polatuzumab Vedotin Priority Review for DLBCL

February 19, 2019 – The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab (BR) for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to Genentech (Roche), the manufacturer of the antibody-drug conjugate (ADC). Genentech’s biologics license application (BLA) for polatuzumab vedotin is based on results from the phase Ib/II GO29365 … (leggi tutto)